Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 198

1.

[Thorax/Lung and Mediastinum, Pleura: Cancer Current Status and Prospects of Immune Checkpoint Inhibitors in the Treatment of Lung Cancer].

Takenoyama M.

Gan To Kagaku Ryoho. 2019 Aug;46(8):1235-1236. Japanese. No abstract available.

PMID:
31501363
2.

A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors.

Doi T, Muro K, Ishii H, Kato T, Tsushima T, Takenoyama M, Oizumi S, Gemmoto K, Suna H, Enokitani K, Kawakami T, Nishikawa H, Yamamoto N.

Clin Cancer Res. 2019 Aug 27. doi: 10.1158/1078-0432.CCR-19-1090. [Epub ahead of print]

PMID:
31455681
3.

Three-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: Pooled analysis of ONO-4538-05 and ONO-4538-06 studies.

Horinouchi H, Nishio M, Hida T, Nakagawa K, Sakai H, Nogami N, Atagi S, Takahashi T, Saka H, Takenoyama M, Katakami N, Tanaka H, Takeda K, Satouchi M, Isobe H, Maemondo M, Goto K, Hirashima T, Minato K, Sumiyoshi N, Tamura T.

Cancer Med. 2019 Sep;8(11):5183-5193. doi: 10.1002/cam4.2411. Epub 2019 Jul 29.

4.

Short progression-free survival of ALK inhibitors sensitive to secondary mutations in ALK-positive NSCLC patients.

Haratake N, Seto T, Takamori S, Toyozawa R, Nosaki K, Miura N, Ohba T, Toyokawa G, Taguchi K, Yamaguchi M, Shimokawa M, Takenoyama M.

Thorac Cancer. 2019 Sep;10(9):1779-1787. doi: 10.1111/1759-7714.13143. Epub 2019 Jul 23.

5.

Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT).

Okada M, Kijima T, Aoe K, Kato T, Fujimoto N, Nakagawa K, Takeda Y, Hida T, Kanai K, Imamura F, Oizumi S, Takahashi T, Takenoyama M, Tanaka H, Hirano J, Namba Y, Ohe Y.

Clin Cancer Res. 2019 Sep 15;25(18):5485-5492. doi: 10.1158/1078-0432.CCR-19-0103. Epub 2019 Jun 4.

PMID:
31164373
6.

The Influence of Clinical T Factor on Predicting Pathologic N Factor in Resected Lung Cancer.

Shimamatsu S, Takenoyama M, Shimokawa M, Takada K, Edagawa M, Toyozawa R, Nosaki K, Oba T, Tagawa T, Yamaguchi M, Taguchi K, Seto T.

Ann Thorac Surg. 2019 Oct;108(4):1080-1086. doi: 10.1016/j.athoracsur.2019.04.026. Epub 2019 May 16.

PMID:
31103386
7.

Corrigendum to "Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan" [Lung Cancer, 129 (March) (2019) 55-62].

Watanabe S, Yoshioka H, Sakai H, Hotta K, Takenoyama M, Yamada K, Sugawara S, Takiguchi Y, Hosomi Y, Tomii K, Niho S, Yamamoto N, Nishio M, Ohe Y, Kato T, Takahashi T, Kamada A, Suzukawa K, Omori Y, Enatsu S, Nakagawa K, Tamura T.

Lung Cancer. 2019 Jun;132:157-158. doi: 10.1016/j.lungcan.2019.04.010. Epub 2019 Apr 20. No abstract available.

8.

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan.

Watanabe S, Yoshioka H, Sakai H, Hotta K, Takenoyama M, Yamada K, Sugawara S, Takiguchi Y, Hosomi Y, Tomii K, Niho S, Yamamoto N, Nishio M, Ohe Y, Kato T, Takahashi T, Kamada A, Suzukawa K, Omori Y, Enatsu S, Nakagawa K, Tamura T.

Lung Cancer. 2019 Mar;129:55-62. doi: 10.1016/j.lungcan.2019.01.005. Epub 2019 Jan 16. Erratum in: Lung Cancer. 2019 Jun;132:157-158.

9.

Outcomes and prognostic factors after pulmonary metastasectomy in patients with colorectal cancer with previously resected hepatic metastases.

Shimizu K, Ohtaki Y, Okumura T, Boku N, Horio H, Takenoyama M, Yamashita M, Hyodo I, Mori K, Kondo H.

J Thorac Cardiovasc Surg. 2019 May;157(5):2049-2057.e1. doi: 10.1016/j.jtcvs.2018.12.075. Epub 2019 Jan 11.

PMID:
30745042
10.

Pneumonectomy after induction chemoradiotherapy for locally advanced non-small cell lung cancer: should curative intent pulmonary resection be avoided?

Yamaguchi M, Shimamatsu S, Edagawa M, Hirai F, Toyozawa R, Nosaki K, Seto T, Takenoyama M, Ichinose Y.

Surg Today. 2019 Mar;49(3):197-205. doi: 10.1007/s00595-018-1751-7. Epub 2019 Jan 4.

PMID:
30610361
11.

ASO Author Reflections: C-Reactive Protein/Albumin Ratio as a Prognostic Factor in Patients with Malignant Pleural Mesothelioma: What Does the Novel Index Represent?

Takamori S, Takenoyama M.

Ann Surg Oncol. 2018 Dec;25(Suppl 3):958-959. doi: 10.1245/s10434-018-6920-9. Epub 2018 Oct 23. No abstract available.

PMID:
30353392
12.

A phase II randomized trial of adjuvant chemotherapy with S-1 versus S-1 plus cisplatin for completely resected pathological stage II/IIIA non-small cell lung cancer.

Okamoto T, Yano T, Shimokawa M, Takeo S, Yamazaki K, Sugio K, Takenoyama M, Nagashima A, Tsukamoto S, Hamatake M, Yokoyama H, Ueda H, Motohiro A, Tagawa T, Shoji F, Kometani T, Saito G, Fukuyama Y, Toyokawa G, Osoegawa A, Emi Y, Maehara Y; Kyushu University Lung Surgery Study Group (KLSS) Japan.

Lung Cancer. 2018 Oct;124:255-259. doi: 10.1016/j.lungcan.2018.08.015. Epub 2018 Aug 19.

PMID:
30268470
13.

[Thorax/Lung and Mediastinum, Pleura: Cancer Current Treatment Strategy for Locally Advanced Non-Small Cell Lung Cancer].

Takenoyama M.

Gan To Kagaku Ryoho. 2018 Aug;45(8):1147. Japanese. No abstract available.

PMID:
30158407
14.

A Randomized Phase III Study Comparing Carboplatin With Nab-Paclitaxel Versus Docetaxel for Elderly Patients With Squamous-Cell Lung Cancer: Study Protocol.

Kogure Y, Saka H, Takiguchi Y, Atagi S, Kurata T, Ebi N, Inoue A, Kubota K, Takenoyama M, Seto T, Kada A, Yamanaka T, Ando M, Yamamoto N, Gemma A, Ichinose Y.

Clin Lung Cancer. 2018 Sep;19(5):e711-e715. doi: 10.1016/j.cllc.2018.05.005. Epub 2018 May 19.

PMID:
29861395
15.

A case of different EGFR mutations in surgically resected synchronous triple lung cancer.

Haratake N, Takenoyama M, Edagawa M, Shimamatsu S, Toyozawa R, Nosaki K, Hirai F, Yamaguchi M, Taguchi K, Seto T, Ichinose Y.

J Thorac Dis. 2018 Apr;10(4):E255-E259. doi: 10.21037/jtd.2018.03.105.

16.

The influence of comorbidity on the postoperative survival in elderly (≥ 75 years old) with lung cancer.

Yano T, Shimokawa M, Kawashima O, Takenoyama M, Yamashita Y, Fukami T, Ueno T, Yatsuyanagi E, Fukuyama S; National Hospital Organization Network Collaborative Research—Thoracic Oncology Group.

Gen Thorac Cardiovasc Surg. 2018 Jun;66(6):344-350. doi: 10.1007/s11748-018-0919-9. Epub 2018 Apr 3.

PMID:
29616463
17.

The C-Reactive Protein/Albumin Ratio is a Novel Significant Prognostic Factor in Patients with Malignant Pleural Mesothelioma: A Retrospective Multi-institutional Study.

Takamori S, Toyokawa G, Shimokawa M, Kinoshita F, Kozuma Y, Matsubara T, Haratake N, Akamine T, Hirai F, Seto T, Tagawa T, Takenoyama M, Ichinose Y, Maehara Y.

Ann Surg Oncol. 2018 Jun;25(6):1555-1563. doi: 10.1245/s10434-018-6385-x. Epub 2018 Mar 2.

PMID:
29500763
18.

Phase 3 study of ceritinib vs chemotherapy in ALK-rearranged NSCLC patients previously treated with chemotherapy and crizotinib (ASCEND-5): Japanese subset.

Kiura K, Imamura F, Kagamu H, Matsumoto S, Hida T, Nakagawa K, Satouchi M, Okamoto I, Takenoyama M, Fujisaka Y, Kurata T, Ito M, Tokushige K, Hatano B, Nishio M.

Jpn J Clin Oncol. 2018 Apr 1;48(4):367-375. doi: 10.1093/jjco/hyy016.

19.

Which Primary Organ Is Most Suitable for Performing Pulmonary Metastasectomy?

Hirai F, Kinoshita I, Matsubara T, Haratake N, Kouzuma Y, Takamori S, Akamine T, Toyokawa G, Tagawa T, Takenoyama M, Maehara Y.

Anticancer Res. 2018 Feb;38(2):1041-1045.

PMID:
29374738
20.

Prevalence of Delta-like protein 3 expression in patients with small cell lung cancer.

Tanaka K, Isse K, Fujihira T, Takenoyama M, Saunders L, Bheddah S, Nakanishi Y, Okamoto I.

Lung Cancer. 2018 Jan;115:116-120. doi: 10.1016/j.lungcan.2017.11.018. Epub 2017 Nov 22.

PMID:
29290251
21.

A typical carcinoid tumor of the lung presenting with pure persistent ground-glass opacity on high-resolution computed tomography: a case report.

Yamaguchi M, Hirai F, Taguchi K, Toyozawa R, Edagawa M, Shimamatsu S, Nosaki K, Seto T, Takenoyama M, Ichinose Y.

Surg Case Rep. 2017 Oct 4;3(1):108. doi: 10.1186/s40792-017-0382-3.

22.

Surgical resection of a well-differentiated inflammatory liposarcoma of the middle mediastinum: a case report.

Edagawa M, Haratake N, Shimamatsu S, Toyozawa R, Nosaki K, Hirai F, Yamaguchi M, Taguchi K, Kaneko K, Seto T, Takenoyama M, Ichinose Y.

J Thorac Dis. 2017 Aug;9(8):E689-E693. doi: 10.21037/jtd.2017.07.90.

23.

A randomized phase II study to assess the effect of adjuvant immunotherapy using α-GalCer-pulsed dendritic cells in the patients with completely resected stage II-IIIA non-small cell lung cancer: study protocol for a randomized controlled trial.

Saka H, Kitagawa C, Ichinose Y, Takenoyama M, Ibata H, Kato T, Takami K, Yamashita M, Maeda T, Takeo S, Ueda H, Okabayashi K, Nagashima S, Oka T, Kouso H, Fukuyama S, Yoshimoto K, Shimokawa M, Saito AM, Ito S.

Trials. 2017 Sep 15;18(1):429. doi: 10.1186/s13063-017-2103-4.

24.

Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer.

Nishio M, Hida T, Atagi S, Sakai H, Nakagawa K, Takahashi T, Nogami N, Saka H, Takenoyama M, Maemondo M, Ohe Y, Nokihara H, Hirashima T, Tanaka H, Fujita S, Takeda K, Goto K, Satouchi M, Isobe H, Minato K, Sumiyoshi N, Tamura T.

ESMO Open. 2017 Mar 7;1(4):e000108. doi: 10.1136/esmoopen-2016-000108. eCollection 2016.

25.

[Thorax/Lung and Mediastinum, Pleura: Cancer Immunotherapy for Lung Cancer - The Beginning of a New Era in the Treatment of Lung Cancer].

Takenoyama M.

Gan To Kagaku Ryoho. 2017 Aug;44(8):644-645. Japanese. No abstract available.

PMID:
28860433
26.

Evaluation of erlotinib for the treatment of patients with non-small cell lung cancer with epidermal growth factor receptor wild type.

Hirai F, Edagawa M, Shimamatsu S, Toyozawa R, Toyokawa G, Nosaki K, Yamaguchi M, Seto T, Takenoyama M, Ichinose Y.

Oncol Lett. 2017 Jul;14(1):306-312. doi: 10.3892/ol.2017.6118. Epub 2017 May 4.

27.

Phase I study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced non-small-cell lung cancer.

Otsubo K, Nosaki K, Imamura CK, Ogata H, Fujita A, Sakata S, Hirai F, Toyokawa G, Iwama E, Harada T, Seto T, Takenoyama M, Ozeki T, Mushiroda T, Inada M, Kishimoto J, Tsuchihashi K, Suina K, Nagano O, Saya H, Nakanishi Y, Okamoto I.

Cancer Sci. 2017 Sep;108(9):1843-1849. doi: 10.1111/cas.13309. Epub 2017 Jul 26.

28.

Uncommon features of surgically resected ALK-positive cavitary lung adenocarcinoma: a case report.

Takamori S, Yamaguchi M, Taguchi K, Edagawa M, Shimamatsu S, Toyozawa R, Nosaki K, Hirai F, Seto T, Takenoyama M, Ichinose Y.

Surg Case Rep. 2017 Dec;3(1):46. doi: 10.1186/s40792-017-0322-2. Epub 2017 Mar 20.

29.

The Controlling Nutritional Status Score Is a Significant Independent Predictor of Poor Prognosis in Patients With Malignant Pleural Mesothelioma.

Takamori S, Toyokawa G, Taguchi K, Edagawa M, Shimamatsu S, Toyozawa R, Nosaki K, Seto T, Hirai F, Yamaguchi M, Shoji F, Okamoto T, Takenoyama M, Ichinose Y.

Clin Lung Cancer. 2017 Jul;18(4):e303-e313. doi: 10.1016/j.cllc.2017.01.008. Epub 2017 Feb 2.

PMID:
28274690
30.

Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non-small cell lung cancer.

Hida T, Nishio M, Nogami N, Ohe Y, Nokihara H, Sakai H, Satouchi M, Nakagawa K, Takenoyama M, Isobe H, Fujita S, Tanaka H, Minato K, Takahashi T, Maemondo M, Takeda K, Saka H, Goto K, Atagi S, Hirashima T, Sumiyoshi N, Tamura T.

Cancer Sci. 2017 May;108(5):1000-1006. doi: 10.1111/cas.13225. Epub 2017 Apr 26.

31.

A case of anticoagulant treatment-resistant Trousseau syndrome controlled by treatment of the underlying lung adenocarcinoma: Utility of monitoring D-dimer levels.

Kuwahata S, Takenaka T, Yasuda S, Sakoda T, Taniyama H, Nagata Y, Iwakawa J, Matsumoto S, Seto T, Takenoyama M, Abe S, Ohishi M.

J Cardiol Cases. 2016 Dec 24;15(2):65-69. doi: 10.1016/j.jccase.2016.10.010. eCollection 2017 Feb.

32.

[Thorax/Lung and Mediastinum, Pleura: Cancer T Factor in Lung Adenocarcinoma].

Takenoyama M, Ichinose Y.

Gan To Kagaku Ryoho. 2016 Aug;43(8):953-4. Japanese. No abstract available.

PMID:
27996224
33.

Molecular Factors Associated with Pemetrexed Sensitivity According to Histological Type in Non-small Cell Lung Cancer.

Yoshida T, Okamoto T, Yano T, Takada K, Kohno M, Suda K, Takenoyama M, Oda Y, Maehara Y.

Anticancer Res. 2016 Dec;36(12):6319-6326.

PMID:
27919952
34.

W'ALK' Into the Next Stage.

Toyokawa G, Seto T, Takenoyama M, Ichinose Y.

Clin Lung Cancer. 2017 Mar;18(2):122-126. doi: 10.1016/j.cllc.2016.10.005. Epub 2016 Oct 26. Review.

PMID:
27865624
35.

Pulmonary Resection for Synchronous M1b-cStage IV Non-Small Cell Lung Cancer Patients.

Yamaguchi M, Edagawa M, Suzuki Y, Toyozawa R, Hirai F, Nosaki K, Seto T, Takenoyama M, Ichinose Y.

Ann Thorac Surg. 2017 May;103(5):1594-1599. doi: 10.1016/j.athoracsur.2016.08.098. Epub 2016 Nov 15.

PMID:
27863731
36.

The Prognostic Impact of Jumonji Domain-containing 2B in Patients with Resected Lung Adenocarcinoma.

Toyokawa G, Taguchi K, Edagawa M, Shimamatsu S, Toyozawa R, Nosaki K, Hirai F, Yamaguchi M, Shimokawa M, Seto T, Takenoyama M, Hamamoto R, Sugio K, Ichinose Y.

Anticancer Res. 2016 Sep;36(9):4841-6.

PMID:
27630338
37.

A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711 L (PEOPLE Study).

Iwata T, Yoshino I, Yoshida S, Ikeda N, Tsuboi M, Asato Y, Katakami N, Sakamoto K, Yamashita Y, Okami J, Mitsudomi T, Yamashita M, Yokouchi H, Okubo K, Okada M, Takenoyama M, Chida M, Tomii K, Matsuura M, Azuma A, Iwasawa T, Kuwano K, Sakai S, Hiroshima K, Fukuoka J, Yoshimura K, Tada H, Nakagawa K, Nakanishi Y; West Japan Oncology Group.

Respir Res. 2016 Jul 22;17(1):90. doi: 10.1186/s12931-016-0398-4.

38.

Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors.

Shimizu T, Seto T, Hirai F, Takenoyama M, Nosaki K, Tsurutani J, Kaneda H, Iwasa T, Kawakami H, Noguchi K, Shimamoto T, Nakagawa K.

Invest New Drugs. 2016 Jun;34(3):347-54. doi: 10.1007/s10637-016-0347-6. Epub 2016 Mar 22.

39.

Clinical role of a new prognostic score using platelet-to-lymphocyte ratio in patients with malignant pleural mesothelioma undergoing extrapleural pneumonectomy.

Tagawa T, Anraku M, Morodomi Y, Takenaka T, Okamoto T, Takenoyama M, Ichinose Y, Maehara Y, Cho BC, Feld R, Tsao MS, Leighl N, Bezjak A, Keshavjee S, de Perrot M.

J Thorac Dis. 2015 Nov;7(11):1898-906. doi: 10.3978/j.issn.2072-1439.2015.11.15. Erratum in: J Thorac Dis. 2016 Jan;8(1):E161.

40.

Mutations of the EGFR, K-ras, EML4-ALK, and BRAF genes in resected pathological stage I lung adenocarcinoma.

Ohba T, Toyokawa G, Osoegawa A, Hirai F, Yamaguchi M, Taguchi K, Seto T, Takenoyama M, Ichinose Y, Sugio K.

Surg Today. 2016 Sep;46(9):1091-8. doi: 10.1007/s00595-015-1295-z. Epub 2015 Dec 28.

PMID:
26711128
41.

Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?

Toyokawa G, Seto T, Takenoyama M, Ichinose Y.

Cancer Metastasis Rev. 2015 Dec;34(4):797-805. doi: 10.1007/s10555-015-9592-y. Review.

42.

How should we manage small focal pure ground-glass opacity nodules on high-resolution computed tomography? A single institute experience.

Yamaguchi M, Furuya A, Edagawa M, Taguchi K, Shimamatsu S, Toyokawa G, Toyozawa R, Nosaki K, Hirai F, Seto T, Takenoyama M, Ichinose Y.

Surg Oncol. 2015 Sep;24(3):258-63. doi: 10.1016/j.suronc.2015.08.004. Epub 2015 Aug 13.

PMID:
26298200
43.

Influence of the distance between home and the hospital on patients with surgically resected non-small-cell lung cancer.

Takenaka T, Inamasu E, Yoshida T, Toyokawa G, Nosaki K, Hirai F, Yamaguchi M, Seto T, Takenoyama M, Ichinose Y.

Eur J Cardiothorac Surg. 2016 Mar;49(3):842-6. doi: 10.1093/ejcts/ezv253. Epub 2015 Jul 22.

PMID:
26201956
44.

Feasibility of cisplatin/pemetrexed with 15 mg/kg bevacizumab for the treatment of patients with advanced non-squamous non-small cell lung cancer.

Hirai F, Seto T, Inamasu E, Shimokawa M, Toyokawa G, Yoshida T, Nosaki K, Takenaka T, Yamaguchi M, Takenoyama M, Ichinose Y.

Oncol Lett. 2015 Jun;9(6):2577-2582. Epub 2015 Mar 30.

45.

Identification of a Novel ALK G1123S Mutation in a Patient with ALK-rearranged Non-small-cell Lung Cancer Exhibiting Resistance to Ceritinib.

Toyokawa G, Inamasu E, Shimamatsu S, Yoshida T, Nosaki K, Hirai F, Yamaguchi M, Seto T, Takenoyama M, Ichinose Y.

J Thorac Oncol. 2015 Jul;10(7):e55-7. doi: 10.1097/JTO.0000000000000509. No abstract available.

46.

Post-recurrence survival of elderly patients 75 years of age or older with surgically resected non-small cell lung cancer.

Takenaka T, Inamasu E, Yoshida T, Toyokawa G, Nosaki K, Hirai F, Yamaguchi M, Seto T, Takenoyama M, Ichinose Y.

Surg Today. 2016 Apr;46(4):430-6. doi: 10.1007/s00595-015-1200-9. Epub 2015 Jun 13.

PMID:
26070907
47.

Preoperative concurrent chemoradiotherapy followed by extrapleural pneumonectomy for patients with non-small cell lung cancer with malignant pleural effusion and/or pleural nodules: Ten-year results of a prematurely terminated single institute phase II trial.

Yamaguchi M, Ichinose Y, Shimamatsu S, Yoshida T, Toyokawa G, Nosaki K, Hirai F, Seto T, Takenoyama M.

Surg Oncol. 2015 Jun;24(2):78-83. doi: 10.1016/j.suronc.2015.02.004. Epub 2015 Mar 26.

PMID:
25818753
48.

Role of surgical resection for patients with limited disease-small cell lung cancer.

Takenaka T, Takenoyama M, Inamasu E, Yoshida T, Toyokawa G, Nosaki K, Hirai F, Yamaguchi M, Shimokawa M, Seto T, Ichinose Y.

Lung Cancer. 2015 Apr;88(1):52-6. doi: 10.1016/j.lungcan.2015.01.010. Epub 2015 Jan 23.

PMID:
25662387
49.

Secondary mutations at I1171 in the ALK gene confer resistance to both Crizotinib and Alectinib.

Toyokawa G, Hirai F, Inamasu E, Yoshida T, Nosaki K, Takenaka T, Yamaguchi M, Seto T, Takenoyama M, Ichinose Y.

J Thorac Oncol. 2014 Dec;9(12):e86-7. doi: 10.1097/JTO.0000000000000358. No abstract available.

50.

Clinical Significance of Detecting Somatic Gene Mutations in Surgically Resected Adenosquamous Cell Carcinoma of the Lung in Japanese Patients.

Morodomi Y, Okamoto T, Takenoyama M, Takada K, Katsura M, Suzuki Y, Fujishita T, Kitahara H, Shimamatsu S, Kohno M, Tagawa T, Okano S, Taguchi K, Ichinose Y, Maehara Y.

Ann Surg Oncol. 2015 Aug;22(8):2593-8. doi: 10.1245/s10434-014-4218-0. Epub 2014 Nov 6.

PMID:
25373537

Supplemental Content

Loading ...
Support Center